NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Tuesday, February, 11th. The medical research company reported $0.54 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.91. The medical research company earned $295.58 million during the quarter, compared to analyst estimates of $294.39 million. EXACT Sciences had a negative return on equity of 18.78% and a negative net margin of 9.59%. View EXACT Sciences' Earnings History.

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for EXACT Sciences.

EXACT Sciences updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.61-1.645 billion, compared to the consensus revenue estimate of $1.59 billion.

15 brokers have issued 12-month price targets for EXACT Sciences' shares. Their forecasts range from $105.00 to $143.00. On average, they anticipate EXACT Sciences' share price to reach $124.77 in the next year. This suggests a possible upside of 54.1% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

Media headlines about EXAS stock have trended negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. EXACT Sciences earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for EXACT Sciences.

EXACT Sciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 15,120,000 shares, an increase of 5.1% from the January 15th total of 14,380,000 shares. Based on an average trading volume of 2,370,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 11.8% of the shares of the company are sold short. View EXACT Sciences' Current Options Chain.

Some companies that are related to EXACT Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and United Therapeutics (UTHR).

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), Advanced Micro Devices (AMD), Square (SQ) and AT&T (T).

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (4.33%), Artisan Partners Limited Partnership (1.69%), Victory Capital Management Inc. (1.23%), Geode Capital Management LLC (1.21%), Zevenbergen Capital Investments LLC (1.20%) and Victory Capital Management Inc. (1.15%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Alliancebernstein L.P., First Trust Advisors LP, Zevenbergen Capital Investments LLC, AJO LP, Dai Ichi Life Insurance Company Ltd, Victory Capital Management Inc. and Eagle Asset Management Inc.. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Artisan Partners Limited Partnership, Marshall Wace North America L.P., Factory Mutual Insurance Co., D1 Capital Partners L.P., Spyglass Capital Management LLC, Partner Fund Management L.P. and National Pension Service. View Insider Buying and Selling for EXACT Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $80.95.

EXACT Sciences has a market capitalization of $11.98 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

The official website for EXACT Sciences is http://www.exactsciences.com/.

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.